Isradipine detailed information: Difference between revisions

Jump to navigation Jump to search
m (Protected "Isradipine detailed information": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
Line 26: Line 26:
{{CMG}}
{{CMG}}


{{Editor Join}}
 


==[[Isradipine (patient information)|For patient information, click here]]==
==[[Isradipine (patient information)|For patient information, click here]]==

Revision as of 16:36, 9 August 2012

Isradipine detailed information
Clinical data
ATC code
Pharmacokinetic data
Protein binding95%
Elimination half-life8 hours
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H21N3O5
Molar mass371.387 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


For patient information, click here

Overview

Isradipine (tradenames DynaCirc, Prescal) is a calcium channel blocker of the dihydropyridine class. It is usually prescribed for the treatment of high blood pressure in order to reduce the risk of stroke and heart attack. More recent research suggests that isradipine may have potential uses for treating Parkinson's disease (Chan et al, 2007).

Further reading

  • Hattori T, Wang P (2006). "Calcium antagonist isradipine-induced calcium influx through nonselective cation channels in human gingival fibroblasts". Eur J Med Res. 11 (3): 93–6. PMID 16751108.
  • Ganz M, Mokabberi R, Sica D (2005). "Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study". J Clin Hypertens (Greenwich). 7 (4 Suppl 1): 27–31. PMID 15858400.
  • Johnson B, Roache J, Ait-Daoud N, Wallace C, Wells L, Dawes M, Wang Y (2005). "Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects". Int J Neuropsychopharmacol. 8 (2): 203–13. PMID 15850499.
  • Fletcher H, Roberts G, Mullings A, Forrester T (1999). "An open trial comparing isradipine with hydralazine and methyl dopa in the treatment of patients with severe pre-eclampsia". J Obstet Gynaecol. 19 (3): 235–8. PMID 15512286.

External links

Template:Calcium channel blockers

de:Isradipin


Template:WikiDoc Sources